InvestorsHub Logo
icon url

rosemountbomber

02/08/22 1:21 PM

#369314 RE: lettruthringout #369313

Well a little better than NICE but still not the best.
icon url

Thonn

02/08/22 1:30 PM

#369315 RE: lettruthringout #369313

and mineral oil comes back… Amarin needs to do something more aggressive about that, or it will continue to appear in the recommendations of all European countries.
icon url

iryokabu

02/08/22 2:25 PM

#369327 RE: lettruthringout #369313

Thank you for sharing the info
icon url

Number sleven

02/08/22 3:06 PM

#369336 RE: lettruthringout #369313

LTRO, Thanks for the information. So according to this committee, Vascepa offers no medical benefits. At the same time the EMA has given us a broad label, and the medical societies have declared Vascepa a standard of care. Is this normal procedure for these committees?
Sleven,
icon url

Whalatane

02/08/22 3:09 PM

#369339 RE: lettruthringout #369313

Thx for the update
Basically only for secondary prevention in the R-IT profile ....that the UK NICE will probably match if AMRN gives them a 10-15% discount to meet their QLAY specification .
Kiwi